Active Ingredient(s): Eptinezumab-jjmr
FDA Approved: * February 21, 2020
Pharm Company: * Lundbeck Seattle BioPharmaceuticals, Inc.
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyepti Overview

Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults.[2] It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[3][4] It is administered by intravenous infusion every three months.[2] Eptinezumab-jjmr was approved for use in the United States in February 2020.[5][6] Contents 1 History 2 See also...

Read more Vyepti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eptinezumab

Recent Vyepti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 100mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vyepti: (1 result)

Sorted by National Drug Code
  • 67386-130 Vyepti 100 mg/ml Intravenous Injection by Lundbeck Pharmaceuticals LLC

Other drugs which contain Eptinezumab-jjmr or a similar ingredient: (1 result)